SCHEMBL10043735

SCHEMBL10043735

Cc1cc2c(cn1)cc(-c1cc(NC(=O)c3ccncc3)ccc1C)c(=O)n2C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.48
ABL1 P00519 3/20 0.45
POLB P06746 2/20 0.44
MAPT P10636 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
FGFR1 P11362 1/20 0.42
SRC P12931 1/20 0.42
MAPK14 Q16539 3/20 0.42
EGFR P00533 1/20 0.42
LCK P06239 1/20 0.42
CSF1R P07333 1/20 0.42
KDR P35968 1/20 0.42
ERBB4 Q15303 1/20 0.42
BRPF1 P55201 1/20 0.41
RAF1 P04049 3/20 0.41
BRAF P15056 3/20 0.41
GAA P10253 1/20 0.40
LMNA P02545 1/20 0.40
MAPK1 P28482 1/20 0.40
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043705 0.92 MAPT (0.54) SYKABL1POLBMAPTMAPK14
SCHEMBL10043699 0.91 SYK (0.57) SYKPOLBMAPTFGFR1SRC
SCHEMBL14011578 0.90 FGFR1 (0.48) SYKABL1POLBMAPTL3MBTL1
SCHEMBL10043664 0.89 SYK (0.49) SYKABL1POLBMAPTL3MBTL1
SCHEMBL10043663 0.89 SYK (0.51) SYKABL1POLBMAPTMAPK14
SCHEMBL10043675 0.89 SYK (0.49) SYKABL1POLBMAPTFGFR1
SCHEMBL10043690 0.88 KCNK3 (0.48) SYKABL1POLBMAPTRAF1
SCHEMBL10043665 0.88 SYK (0.46) SYKABL1POLBMAPTMAPK14
SCHEMBL10043667 0.88 MEN1 (0.47) SYKABL1POLBMAPTFGFR1
SCHEMBL10043669 0.88 RAB9A (0.51) SYKABL1POLBMAPTFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885ABL1 59/4885POLB 4382/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885ABL1 59/4885POLB 4382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.